Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

199
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
199
Cancer Therapies02:49

Cancer Therapies

7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
147
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

215
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
215
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

173
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
173
Cancer Survival Analysis01:21

Cancer Survival Analysis

321
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
321

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exercise training for cardiovascular prevention in patients with cancer.

European heart journal·2026
Same author

Beyond Chronological Age: Why Frailty Matters in Heart Failure.

European journal of heart failure·2026
Same author

Effect of heart rate reduction with ivabradine on quality of life in advanced cancer patients.

ESC heart failure·2026
Same author

Erythropoiesis-stimulating agents in anaemic patients with HF-a lost cause?

European journal of heart failure·2026
Same author

The EMPATICC-trial-should location shape therapy?

European heart journal·2026
Same author

The Prognostic Role of Frailty and Its Recognition With Simple FRAIL and Fried Frailty Questionnaires in Advanced Cancer Patients.

Journal of cachexia, sarcopenia and muscle·2025

Related Experiment Video

Updated: May 27, 2025

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

16.1K

Weight Gain Among Cancer Patients Receiving Chemotherapy-Facts and Numbers.

Muhammad Shahzeb Khan1,2,3, Javed Butler3,4, Markus Anker5,6,7,8

  • 1Department of Medicine, Baylor College of Medicine, Temple, Texas, USA.

Journal of Cachexia, Sarcopenia and Muscle
|February 20, 2025
PubMed
Summary

Weight gain in cancer patients, particularly those with non-small cell lung cancer, is linked to improved survival outcomes. Strategies to promote weight gain and prevent loss are clinically significant for better patient prognosis.

Keywords:
cancer patientschemotherapyfacts and numbersweight gain

More Related Videos

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

696
Ultrasonographic Evaluation of Breast Cancer-related Lymphedema
05:44

Ultrasonographic Evaluation of Breast Cancer-related Lymphedema

Published on: January 12, 2017

9.3K

Related Experiment Videos

Last Updated: May 27, 2025

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

16.1K
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

696
Ultrasonographic Evaluation of Breast Cancer-related Lymphedema
05:44

Ultrasonographic Evaluation of Breast Cancer-related Lymphedema

Published on: January 12, 2017

9.3K

Area of Science:

  • Oncology
  • Clinical Nutrition
  • Cancer Research

Background:

  • Cachexia is prevalent in lung cancer, affecting up to 80% in advanced stages and causing mortality in 20% of cases.
  • Weight gain exceeding 5% is observed in 18.3% of cancer patients undergoing chemotherapy across various cancer types.
  • Weight loss is a common endpoint in cachexia trials, yet data on weight gain as a positive outcome marker is limited.

Discussion:

  • Weight gain of >5% within 3 months in non-small cell lung cancer (NSCLC) patients correlates with improved overall survival (OS) and progression-free survival (PFS).
  • A post hoc analysis demonstrated that weight gain of any percentage (>0%, >2.5%, >5%) within 3 months in NSCLC patients showed comparable significant benefits in OS and PFS.
  • These findings underscore the importance of interventions aimed at promoting weight gain and preventing weight loss in cancer patients.

Key Insights:

  • Weight gain, not just weight loss, is a critical prognostic indicator in cancer patient management.
  • Even modest weight gain (>0%) shows significant survival benefits in NSCLC patients undergoing chemotherapy.
  • Standardized assessment tools are needed to differentiate beneficial weight gain from pathological fluid retention.

Outlook:

  • Future research should focus on the prognostic value of weight gain and develop strategies to encourage it in cancer patients.
  • Standardized tools are recommended for assessing weight changes to distinguish pathological causes like edema.
  • Monitoring and reporting weight changes should be integrated into all future cancer clinical trials.